Disc-shaped UAP captured on video
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Gilead dives into ‘in vivo' cell therapy with $350M buyout of Interius
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Dive Brief: Gilead Sciences is deepening its investment in cancer cell therapy, announcing Thursday a deal to pay $350 million to buy privately held Interius BioTherapeutics for a technology designed to reprogram immune cells in patients' bodies. If successful, Interius' 'in vivo' approach could yield a simpler alternative to the CAR-T therapies Gilead's Kite Pharma division have brought to market, each of which includes extravagant production processes that involve manipulating cells in a lab. Gilead spent $12 billion to buy Kite nearly a decade ago and, since then, has become a leader in CAR-T therapies. That business has sputtered recently amid declining demand and competition from other developers. But Gilead is still investing through acquisitions and partnerships, such as a collaboration with Arcellx in multiple myeloma. Dive Insight: Cell therapies are something of a double-edged sword. They can powerfully drive cancers into a deep and long-lasting remission, but carry potentially serious safety risks and a burdensome chemotherapy 'conditioning' step. A complex manufacturing process in which a patient's cells are shipped to a lab, modified, and reinfused, limits CAR-T's reach, too. Drugmakers have long tried to simplify the process in one way or another, with limited success. But one approach that's gained traction is so-called in vivo cell therapy, through which companies use technological tools like gene editing or messenger RNA to rewire cells inside the body. Several in vivo cell therapy developers have sprung up in recent years. While their work remains early, they've started to draw the interest of large pharmaceutical companies. AstraZeneca bought startup EsoBiotech in March and, in June, AbbVie followed with a deal for another privately held company, Capstan Therapeutics. Now Gilead has embraced the approach in acquiring Interius, which uses engineered viruses to deliver into certain immune cells instructions for cancer-targeting protein receptors. An experimental drug called INT2104 it's developing is among the first in vivo cell therapies to be tested in humans. An ongoing Phase 1 study is evaluating it in certain blood cancers. The company has also been conducting early research in autoimmune diseases, as well as a third, undisclosed project. The deal 'marks a pivotal step for Interius and the future of in vivo therapy, which has the potential to reduce treatment timelines, broaden access to care and improve outcomes for patients with aggressive or advanced disease,' said Interius CEO Phil Johnson, in a statement. Interius spun out of the University of Pennsylvania in 2021 and raised a $76 million Series A round that year. Gilead will use cash to purchase Interius' shares, which the company said will reduce its 2025 per-share earnings by 23 to 25 cents. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
AAHI Partners with Quratis to Strengthen Global Vaccine Manufacturing and Accelerate Access to Lifesaving Vaccines
SEATTLE, August 21, 2025--(BUSINESS WIRE)--Access to Advanced Health Institute (AAHI), a global leader in translating high-impact science into scalable, field-ready vaccine solutions, today announced an exciting new partnership with Quratis, a premier biotechnology company and advanced Contract Development and Manufacturing Organization (CDMO). This collaboration marks a pivotal step forward in breaking through barriers in global health equity around the world. Under this strategic alliance, Quratis has been selected as AAHI's preferred manufacturer for high-quality pre-clinical and clinical vaccine supplies, with the capacity to expand into commercial-scale production for global markets. This collaboration will accelerate the development of AAHI's innovative vaccine candidates targeting deadly diseases such as tuberculosis, and of vaccines that rely on AAHI's vaccine adjuvants to provide protection against malaria, HIV, and other global health threats. Quratis brings a world-class GMP-certified bioplant and cutting-edge CDMO expertise in biopharmaceutical raw material development, process optimization, and finished pharmaceutical manufacturing. By designating Quratis as preferred partner, AAHI strengthens both its scientific capabilities and access to scalable, cost-effective production of its groundbreaking vaccine formulations—including dry vaccines that eliminate cold chain dependencies and needle-free delivery systems for superior respiratory protection. The partnership ensures a seamless supply chain platform, enabling swift clinical development and broader deployment to the world's most vulnerable populations. "Partnering with Quratis is a very important step in AAHI's strategy to advance practical, life-saving vaccines, that can be deployed at scale where they're needed most," said Keeley Foley, CEO of AAHI. "Quartis' innovative cutting edge, safe, world-class CDMO capabilities makes it possible for AAHI to deliver on our mission – and helps ensure our efforts to combat infectious diseases and foster health autonomy worldwide. Together, we're not just manufacturing vaccines—we're delivering an important mission to revolutionize global health." Quratis, renowned for its global innovation in healthcare, brings unparalleled expertise in vaccine development and manufacturing to the table. With a track record of success in TB and COVID-19 vaccines like QTP101 and QTP104, Quratis' advanced processes will enhance AAHI's pipeline, ensuring high-quality, efficient production from pre-clinical stages through clinical trials. "We are honored and thrilled to join forces with AAHI, a pioneer in immune-enhancing technologies and sustainable vaccine solutions," said Soung Joon Kim, CEO of Quratis. "This partnership aligns perfectly with our vision of making people happy and healthy through borderless healthcare innovations. By supporting AAHI's pipeline, we expect to create value not only for global health, but also for our shareholders through long-term growth opportunities." The partnership builds on existing collaborations, including the co-development of the ID93+GLA-SE tuberculosis vaccine candidate (QTP101), and underscores a shared commitment to strengthening international vaccine supply chains, advancing equitable access, and fostering worldwide manufacturing capacity for sustainable program deployment. For more information about this partnership or to explore collaboration opportunities, and order pre clinical materials please contact info@ About Access to Advanced Health Institute (AAHI) Access to Advanced Health Institute (AAHI) is a global leader in developing practical, cost-effective vaccines to combat deadly diseases such as tuberculosis, malaria, and HIV. With a mission to translate high-impact science into scalable, field-ready solutions, AAHI breaks through barriers in global health by creating innovative vaccine formulations, building worldwide manufacturing capacity, and fostering partnerships to ensure sustainable, equitable health outcomes. For more information, visit or contact us at info@ About Quratis Quratis Inc. is a leading biopharmaceutical company specializing in innovative vaccine development and advanced biologics manufacturing. With a state-of-the-art GMP facility and strong global partnerships, Quratis is at the forefront of developing next-generation vaccines against infectious diseases, including tuberculosis, COVID-19, schistosomiasis, and neglected tropical diseases. In addition to its core vaccine pipeline, Quratis offers superior CDMO capabilities, including expertise in mRNA–LNP drug delivery platforms that provide seamless bench-to-field support from research through commercial production. By combining cutting-edge R&D with scalable manufacturing, Quratis is committed to delivering high-quality, accessible, and life-saving solutions to patients worldwide. For more information, visit View source version on Contacts Casey Felipeinfo@ Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Anduril, Blue Origin to study how to transport cargo from orbit to earth for the Pentagon
Blue Origin and Anduril have landed new study contracts with the U.S. Air Force to explore how their technology, including rockets, could move military cargo around the world. The contracts under the Air Force's Rocket Cargo program are relatively small – Blue Origin's comes in at $1.37 million and Anduril's at $1 million. But they could be the first steps in revolutionizing how the Pentagon transports cargo. Study contracts like these are also a strong signal as to which players will later compete for larger-dollar funding. Anduril's contract is especially intriguing and suggests the defense startup is making forays into an entirely new business line. The two awards fall under the U.S. Air Force Research Laboratory's Rocket Experimentation for Global Agile Logistics (REGAL) program. Blue Origin did not respond to TechCrunch's request for comment, and an Anduril spokesperson directed TechCrunch to AFRL. REGAL is the experimentation arm of AFRL's larger Rocket Cargo program, which is focused on 'delivery as a service' via orbital transport. The Air Force wants to procure these capabilities via service-type contracts, similar to how the DoD contracts commercial airlines. The aim of the REGAL program is to prove out commercial, reusable rockets, reentry systems, and cargo transportation systems to enable deliveries to remote or hard-to-reach theaters in less than an hour. While there isn't much public information about REGAL's scope of work or timeline, the requests for proposals that underly the awards contain some interesting information. Blue's contract, according to the sparse award listing, is for an analysis of how its tech could support 'point-to-point material transportation.' The listed place of performance is Merritt Island, Florida, Blue's home on the Space Coast and where it is developing the heavy-lift New Glenn rocket. Anduril's design study contract, which also falls under REGAL, was awarded under a separate call for proposals called 'Payload Rentry from Space Development and Demonstrations.' Cutting through the jargon, the proposal implies Anduril will study how to develop a reentry container that can carry between 5 tons to 10 tons of payload from Earth and back. The listing, which can be viewed on emphasized that the container needs to work with different rocks and the study should propose a thermal protection system. Anduril's 'payload container,' as the listing calls it, should integrate multiple government-defined payloads and work across platforms. Reentry is a notoriously difficult problem to solve in spaceflight. Developing materials that can survive atmospheric reentry, and a container that doesn't completely destroy the contents involved, is a challenge. A handful of startups, like Varda Space Industries, have developed reentry capsules for in-space manufacturing, and SpaceX's Dragon capsule brings back cargo and astronauts from the ISS. But overall, the number of vendors that can deliver this capability is limited. The news of the two contracts, which haven't been reported, follows on Rocket Lab's own REGAL contract that was announced earlier this year. That contract explicitly has a flight demonstration step, though AFRL hasn't released other details on that award, like the amount. If rocket cargo services mature, the Pentagon could buy 'delivery as a service,' with massive loads riding a commercial heavy rocket and returning to Earth inside a capsule for quick offload. Long term, AFRL said the program could even include point-to-point transportation of humans. Sign in to access your portfolio
